Jack Bendheim Sells 14,184 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 14,184 shares of the company’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08. Following the completion of the sale, the chief executive officer directly owned 50,760 shares of the company’s stock, valued at $2,620,231.20. The trade was a 21.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.
• On Wednesday, January 21st, Jack Bendheim sold 14,687 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.68, for a total value of $612,154.16.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.

Phibro Animal Health Trading Down 0.5%

Shares of Phibro Animal Health stock opened at $51.26 on Friday. The business has a fifty day simple moving average of $40.96 and a 200-day simple moving average of $38.93. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $56.30. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of 22.78, a price-to-earnings-growth ratio of 0.79 and a beta of 0.80. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $373.91 million for the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, equities analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 21.33%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Brooklyn Investment Group raised its stake in shares of Phibro Animal Health by 8.7% in the fourth quarter. Brooklyn Investment Group now owns 6,757 shares of the company’s stock valued at $255,000 after acquiring an additional 538 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after acquiring an additional 6,826 shares during the last quarter. Integrated Quantitative Investments LLC lifted its stake in shares of Phibro Animal Health by 17.2% in the 4th quarter. Integrated Quantitative Investments LLC now owns 38,046 shares of the company’s stock valued at $1,421,000 after purchasing an additional 5,576 shares during the period. Federated Hermes Inc. boosted its position in shares of Phibro Animal Health by 320.2% in the 4th quarter. Federated Hermes Inc. now owns 96,911 shares of the company’s stock worth $3,621,000 after purchasing an additional 73,849 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC grew its stake in shares of Phibro Animal Health by 40.2% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 27,292 shares of the company’s stock worth $1,020,000 after purchasing an additional 7,825 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Analyst Upgrades and Downgrades

PAHC has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday. Morgan Stanley set a $49.00 target price on Phibro Animal Health in a report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Phibro Animal Health in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.